The bigger opportunity hiding between compliance and R&D

Most companies don’t think of chemical regulation and chemical hazard data as connected. Compliance teams track what’s restricted. R&D or toxicology teams look at the science. Each one stays in its own lane. 

I see this play out with customers all the time. We’ll be working with an R&D team on a project, and they’ll say, “oh, our compliance team would find this regulatory list screening useful”. Or the reverse happens: compliance realizes hazard information would have changed how they understood a substance. It’s not a deliberate split. The two functions have typically been set up separately, and few companies have paused to ask what that’s costing them. 

Yet the companies that connect the two aren’t just staying compliant, they’re finding an advantage the rest of the market hasn’t noticed yet.  

Most organizations don’t think of that as chemical intelligence. They think about compliance, or they think about hazard assessment. The opportunity lies in bringing those two perspectives. 

What chemical intelligence brings together

Chemical intelligence sits at the intersection of chemical regulation and chemical science.  

Regulatory information tells you what’s restricted, where, and when requirements change. Staying ahead of those changes is its own discipline, as I’ve written about before in horizon scanning: the missing compliance discipline.  

Hazard information on its own is often partial: a study here, a classification there, sometimes conflicting. Turning that into something usable takes a structured evaluation across relevant hazard endpoints. That’s the role of a chemical hazard assessment, or CHA, independent of whether the substance is regulated yet. 

Developing a CHA takes real scientific work. Our toxicologists build each CHA on a weight-of-evidence approach: experimental data where it exists, modeled and analog data where it doesn’t, and expert judgment to weigh it all when the evidence is mixed or incomplete. That’s the process behind all 26 endpoints they assess, for every chemical. 

Chemical intelligence brings together those regulatory and scientific insights, giving organizations a more complete understanding of the chemicals they use and the regulatory context.   

What compliance and R&D each miss without the other's data

Neither function is doing anything wrong. They’re just working with half the picture.  

Compliance teams know what’s regulated today. What they often don’t have is visibility into a substance’s hazard profile beyond the list it does or doesn’t appear on. R&D and toxicology teams know the science on a substance. What they don’t always track is how that maps to obligations across REACH, TSCA, or the dozens of other frameworks a global business has to navigate. It’s part of a wider visibility gap I’ve explored before in the chemicals you haven’t mapped are your real applicability problem.  

Put those two views together and something changes. A substance that clears every current list can still carry a hazard signal worth watching, the kind that shows up on a watch list or an advisory list before it ever becomes a formal restriction. Looking at regulatory status alone won’t catch that. Looking at the science alone won’t show which markets are actually impacted. 

Separately, both teams are doing their jobs well. Together, they’d catch problems, and opportunities, that neither one sees alone. 

The cost of the gap

This isn’t an abstract efficiency argument. The gap has real commercial consequences. 

Even the simplest products contain multiple chemicals, not one. Every one of them carries its own regulatory status and its own hazard profile. The more chemicals in a product, the more places this gap has to hide. 

Market access depends on it. A substance can be compliant in one jurisdiction and restricted in another. The businesses that catch this early keep moving while others get stuck reformulating under deadline pressure. 

Recalls and reformulations are the expensive version of the same problem. Catching a hazard signal at the design stage costs a formulation review. Catching it after the product has shipped costs a recall. 

Marketing and sustainability claims need to be defensible, not just accurate on the day they’re made. A claim backed by regulatory status alone can unravel if the hazard picture shifts. A claim backed by both regulatory and hazard data, the kind our chemical experts build into a proper assessment, holds up under scrutiny. 

And competitive advantage goes to whoever sees the shift first. Companies making informed decisions about their product formulations earlier than their competitors get to move first on sourcing, or positioning, while everyone else is still reacting.

Start with one step, not a reorganization

None of this requires merging departments or rebuilding how compliance and R&D work.  

The starting point can be much smaller. Even one step, like screening against advisory, watch, or sector lists rather than only what’s currently regulated, brings real benefits: identifying problematic chemicals early, prioritizing what needs attention first, and finding alternatives while there’s still time to choose one.  

The opportunity is already there, sitting in the space between two teams that have never had a reason to compare notes. The companies that close that gap now won’t be reacting to the next regulatory shift. They’ll already understand what it means.